Why BioMarin's Pipeline Could Be Worth $4 Billion-Plus By: Benzinga via Benzinga January 20, 2016 at 14:31 PM EST Credit Suisse issued a report on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) and initiated coverage on the company due to strength ... Read More >> Related Stocks: Biomarin Pharmaceuticals